John M. Rothman
Corporate Officer/Principal en TYME TECHNOLOGIES, INC. .
Cargos activos de John M. Rothman
Empresas | Cargo | Inicio | Fin |
---|---|---|---|
TYME TECHNOLOGIES, INC. | Corporate Officer/Principal | 19/08/2020 | - |
Historial de carrera de John M. Rothman
Antiguos cargos conocidos de John M. Rothman.
Empresas | Cargo | Inicio | Fin |
---|---|---|---|
RACE ONCOLOGY LIMITED | Director Técnico/Científico/I+D | - | 01/10/2019 |
AYALA PHARMACEUTICALS, INC. | Director de Operaciones | 06/11/2009 | 09/12/2011 |
Director Técnico/Científico/I+D | 01/03/2005 | 01/03/2013 | |
Corporate Officer/Principal | 09/12/2011 | 13/08/2012 |
Formación de John M. Rothman.
Tulane University School of Medicine | Doctorate Degree |
Estadísticas
Internacional
Estados Unidos | 4 |
Australia | 2 |
Operativa
Corporate Officer/Principal | 2 |
Chief Tech/Sci/R&D Officer | 2 |
Chief Operating Officer | 1 |
Sectorial
Health Technology | 4 |
Consumer Services | 2 |
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Empresas relacionadas
Empresas cotizadas | 1 |
---|---|
RACE ONCOLOGY LIMITED | Health Technology |
Empresas privadas | 2 |
---|---|
Advaxis, Inc.
Advaxis, Inc. Pharmaceuticals: MajorHealth Technology Advaxis, Inc. is a biotechnology company, which engages in the discovery, development and commercialization of cancer immunotherapies. It manages platform technology that utilizes live attenuated Listeria monocytogenes bioengineered to secrete antigen or adjuvant fusion proteins. The firm has four franchises in various stages of clinical and pre-clinical development, namely: HPV-associated cancers, prostate cancer, neoantigen therapy and hotspot mutation therapy. The company was founded on June 5, 1987 and is headquartered in Princeton, NJ. | Health Technology |
Tyme Technologies, Inc.
Tyme Technologies, Inc. Pharmaceuticals: MajorHealth Technology Tyme Technologies, Inc. operates as a biotechnology company, which engages in the development and commercialization of cancer therapies. It offers a clinical program named SM-88 which is a novel, oral, and monotherapy investigational agent that aims to disrupt the cancer cell's protein synthesis. The company was founded by Steve Hoffman and Michael Demurjian on November 22, 2011 and is headquartered in Bedminster, NJ. | Health Technology |
- Bolsa de valores
- Insiders
- John M. Rothman
- Experiencia